An 8-week Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren/Amlodipine/HCTZ Compared to Aliskiren/Amlodipine in US Minority Patients With Stage 2 Hypertension.

Trial Profile

An 8-week Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren/Amlodipine/HCTZ Compared to Aliskiren/Amlodipine in US Minority Patients With Stage 2 Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2011

At a glance

  • Drugs Aliskiren/amlodipine; Aliskiren/amlodipine/hydrochlorothiazide; Amlodipine
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCENT
  • Most Recent Events

    • 25 Aug 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 25 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top